|
|
News Breaks | | | | March 9, 2012 | | 10:31 EDT |  | HLF, WTW, VNET, JNJ, LPNT, VHS, NLS, JPM, DKS | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Herbalife (HLF) initiated with an Overweight at Barclays...Weight Watchers (WTW) initiated with an Overweight at Barclays...21Vianet Group (VNET) initiated with a Buy at Stifel Nicolaus...Johnson & Johnson (JNJ) initiated with a Hold at Jefferies...LifePoint Hospitals (LPNT) initiated with a Buy at Cantor...Vanguard Health (VHS) initiated with a Buy at Cantor...Nautilus (NLS) initiated with an Outperform at Northland Securities...JPMorgan (JPM) initiated with a Buy at Guggenheim...Dick's (DKS) Sporting initiated with a Buy at Argus. | |
|
News For HLF;WTW;VNET;JNJ;LPNT;VHS;NLS;JPM;DKS From The Last 14 Days Check below for free stories on HLF;WTW;VNET;JNJ;LPNT;VHS;NLS;JPM;DKS the last two weeks. |
|
|
| June 19, 2013 | | 13:50 EDT |  | JNJ | J&J issued FDA warning letter on Xarelto advertising
 Subscribe for More Information | | | 08:45 EDT |  | JNJ | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | 07:57 EDT | | VHS | Wells Faro to host a conference
Subscribe for More Information | | | 06:52 EDT |  | WTW | AMA recognizes obesity as disease. NY Times reports
The American Medical Association, or AMA, has officially recognized obesity as a disease, The New York Times reported yesterday. The decision could cause more insurance companies to pay for obesity treatments and spur more doctors to take more steps to combat the condition, the newspaper stated. The AMA overrode a recommendation by a committee that had recommended against making the change, the newspaper noted. Reference Link | | | June 18, 2013 | | 13:33 EDT | | HLF | Pershing Square: Herbalife's new survey, statements raise questions of legality
Subscribe for More Information | | | 07:34 EDT |  | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | June 17, 2013 | | 16:20 EDT |  | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:28 EDT | | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | | | 09:36 EDT | | JPM | JPMorgan reports May net credit losses 3.34% vs. 3.49% last month
Reports May delinquency rate 1.60% vs. 1.70% last month. | | | 08:09 EDT | | JPM | JPMorgan confirms launch of asset tracking service
Subscribe for More Information | | | 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. | | | 07:50 EDT | | JPM | Move to relaunch synthetic CDOs falls apart, FT reports
Subscribe for More Information | | | 07:42 EDT | | JPM | JPMorgan to begin asset tracking service, FT reports
Subscribe for More Information | | | 07:13 EDT | | JPM | Bank profits seen hurt by rising rates with no growth, Bloomberg reports
Subscribe for More Information | | | 06:14 EDT | | JPM | On the Fly: Periodicals Wrap-Up
Subscribe for More Information | | | June 16, 2013 | | 14:45 EDT | | JNJ | J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says
Subscribe for More Information | | | June 14, 2013 | | 15:49 EDT | | JNJ | J&J's Mentor gets FDA approval for MemoryShape breast implants
Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group. | | | 09:05 EDT | | JPM | JPMorgan says One Equity Partners to raise future funds independently
JPMorgan Chase announced that the partners of One Equity Partners, the firm’s private equity unit, will begin to raise their next fund from an external group of limited partners and become independent from JPMorgan Chase. One Equity Partners currently manages approximately $4.5B of investments for JPMorgan Chase in direct private equity transactions and has produced strong returns over the last twelve years. OEP will continue to make direct investments for JPMorgan Chase for an interim period. OEP will still manage the existing group of portfolio companies for JPMorgan Chase to maximize value for the firm. | | |
|
|
|
|
|
|
